Mental Health Clinics in Ravenna, MI Accepting Medicare
2 Mental Health Clinics found. Showing 1 - 2
 Missi's Place Counseling, Pllc Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 12452 Stafford St Ste A, Ravenna, MI 49451 Phone: 231-798-5220 |
Resfeber Therapy Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 2831 Wunsch Rd, Ravenna, MI 49451 Phone: 616-840-6826 |
News Archive
Large scale study shows success of epilepsy surgery
In one of the largest epilepsy surgery studies ever conducted, Mayo Clinic researchers have found that 81 percent of patients with intractable epilepsy become totally or nearly seizure-free six months following epilepsy surgery. Ten years later, 72 percent remained totally or nearly seizure-free.
Neural mapping approach to re-examine previous Alzheimer's studies finds improved reproducibility
A neural mapping approach that pegs results from more than two dozen previous Alzheimer's studies found that reproducibility improves when trying to isolate symptoms to a brain network rather than a single area of the brain.
New weapon in the fight against obesity and diabetes
A study appearing November 5 in the journal Cell Metabolism demonstrates that a synthetic new chemical entity protects against diet-induced obesity, improves glucose tolerance and insulin sensitivity and enhances exercise endurance by enhancing fat utilization in certain target tissues.
Teach children to wash their hands with a song
And now it's back to nursery rhymes as doctors resort to innovative ways to teach children how to wash their hands properly and curb the spread of infections. An article published in the BMJdescribes this possibility using a common song.
Nymox Pharmaceutical announces new positive results from long term outcome study of NX-1207 for BPH
Nymox Pharmaceutical Corporation today announced new 2010 positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's NX02-0012 and NX02-0013 Phase 1-2 studies of NX-1207 initially undertaken in 2003. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 6 ½ years after a single treatment with NX-1207.
› Verified 2 days ago